Back

Feasibility and safety of early initiation of a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor in patients with acute myocardial infarction undergoing primary PCI

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Pharmacology and Pharmacotherapy ePosters Lipid-Lowering Agents ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Tomoaki Okada

Kagawa Prefectural Central Hospital, Takamatsu (Japan)

56 More presentations in this session

Presentation thumbnail
Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects
Professor Y. Huo (Beijing, CN)
Abstract Slides
Presentation thumbnail
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
Doctor C. Becker (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics
Doctor S. Frechen (Leverkusen, DE)
Abstract Slides
Presentation thumbnail
Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study
Doctor C. Ballantyne (Houston, US)
Abstract Slides
Presentation thumbnail
The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population
Doctor D. Radenkovic (Greater London, GB)
Abstract Slides

Access the full session

Session thumbnail
Pharmacology and Pharmacotherapy ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Where are we now? Decision-making in LDL-C lowering and CV risk
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Congress Presentation
2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources